Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma.

TNT is associated with more frequent complete pathologic response, a higher rate of margin negative resection, and prolonged OS as compared with SF or SMNT. Additional studies to identify subgroups that derive the greatest benefit are warranted.